AdvanSix Inc., a U.S.-based chemical producer specializing in caprolactam and Nylon 6 resin, delivered modest net income growth of 11.6% in 2025 despite a challenging operating environment marked by cyclical industry pressures and regulatory compliance costs. The company's long-term customer contracts and integrated manufacturing facilities underpin a defensible moat but necessitate sustained capital expenditures averaging over $100 million annually. Going forward, maintaining margins amidst raw material cost volatility, environmental regulation tightening, and elevated capex needs will constrain returns, with approximately 6% ROE recorded in 2025. AdvanSix’s disciplined capital allocation includes moderate share buybacks and steady dividends, yet external factors such as trade policies and customer concentration remain material risks.